TLPH News and Press, Talphera Inc. From 05/14/25

2025-05-14 16:07:51 ET More on Talphera Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript AcelRx Pharmaceuticals Q1 2025 Earnings Preview Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad Seeking Alpha’s Qu...

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire Cash and investments at March 31, 2025 , as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025 , were...

Aeva Technologies Inc. (AEVA) is expected to report $-0.59 for Q1 2025 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil) (LND) is expected to report for Q3 2025 Omron Corporation ADR (OMRNY) is expected to report for Q4 2025 Sezzle Inc. (SEZL) is expected to report $0.3...

2025-05-13 17:35:20 ET More on AcelRx Pharmaceuticals Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09 Se...

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 PR Newswire SAN MATEO, Calif. , May 7, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused o...

2025-03-31 18:34:45 ET More on AcelRx Pharmaceuticals Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript AcelRx Pharmaceuticals GAAP EPS of -$0.07 beats by $0.09 Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for Ac...

2025-03-31 18:33:54 ET Talphera, Inc. (TLPH) Q4 2024 Earnings Conference Call March 31, 2025, 04:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Shakil Aslam - CMO Conference Call Participants Thomas Yip - H.C. Wainwright ...

2025-03-31 16:07:17 ET More on AcelRx Pharmaceuticals Seeking Alpha’s Quant Rating on AcelRx Pharmaceuticals Historical earnings data for AcelRx Pharmaceuticals Financial information for AcelRx Pharmaceuticals Read the full article on Seeking Alpha ...

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update PR Newswire The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 Talphera expects the registratio...

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million PR Newswire The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients ...